Merck bets $334m on Korea as Asia-Pacific biopharma hub

German science and technology company Merck has opened a $334 million bioprocessing plant in Daejeon, its largest life science investment in Asia-Pacific, as it seeks to bring production closer to regional drugmakers. The company said Thursday that the 44,500-square-meter facility in Dungok, Daejeon, will manufacture critical materials used in the development and production of biologic medicines, strengthening supply chains for drugmakers across the region. The plant will produce dry powder and

Source: The Korea Herald